



# NECTM9

Northern European  
Conference on Travel Medicine  
Denmark Copenhagen May 22-24 2024



# Factors influencing the immunogenicity of rabies vaccines, evaluation of time effect over several decades

*A literature review and meta-regression*

**Authors:** Fernando Morelli<sup>1</sup>, Christèle Augard<sup>1</sup>, Laurent Coudeville<sup>1</sup>, Catherine Bravo<sup>1</sup>, Hervé Bourhy<sup>2</sup>, Beatriz Quiambao<sup>3</sup>, Sergio Recuenco<sup>4</sup>, Susan Moore<sup>5</sup>

**Affiliations:** 1. Global Medical Department, Sanofi, Lyon, France; 2. Lyssavirus Epidemiology and Neuropathology Unit, Institut Pasteur, Paris, France; 3. Research Institute for Tropical Medicine, Research Drive, Filinvest Corporate City, Alabang, Muntinlupa City, Metro Manila, Philippines; 4. Facultad de Medicina San Fernando, Universidad Nacional Mayor de San Marcos, Lima, Peru; 5. Veterinary Medical Diagnostic Laboratory/One Health Laboratory, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA



# NECTM9

Northern European  
Conference on Travel Medicine  
Denmark Copenhagen May 22-24 2024



## Conflicts of Interest

Fernando Morelli, Christele Augard, Laurent Coudeville and Catherine Bravo are Sanofi employees and may hold share/stock options. Hervé Bourhy receives funding from Humabs BioMed SA on the project PCT/EP2014/003076;18/11/2014 “Antibodies that potentially neutralize rabies virus and other lyssaviruses and uses thereof”. Beatriz Quiambao, Sergio Recuenco, Susan Moore declare no conflict of interest.

Sanofi supported this work.



# NECTM9

Northern European  
Conference on Travel Medicine  
Denmark Copenhagen May 22-24 2024



Rabies causes approximately **59,000 deaths** annually worldwide, with a significant under-reporting likely, affecting both individuals from endemic areas as well as **travellers**.


## Background

Rabies prevention has a long history of effective interventions, mainly due to vaccine access, either with **pre-exposure prophylaxis** (PrEP) or **post-exposure prophylaxis** (PEP). Currently, multiple rabies vaccines are available. They are based on similar viral strains, but prepared using different substrates, such as:



### Human Tissue Culture

human diploid cell vaccine  
(HDCV)



### Primate Tissue Culture

purified Vero cell vaccine  
(PVRV)



### Avian Tissue Culture

purified chick embryo cell vaccine  
(PCECV)



# NECTM9

Northern European  
Conference on Travel Medicine  
Denmark Copenhagen May 22-24 2024



## Background



In a previous systematic literature search and corresponding meta-analysis on these three rabies vaccines (HDCV, PVRV, and PCECV), a trend of **higher Geometric Mean of Rabies Virus Neutralizing Antibody Titers (GMT RVNA)** was observed in studies conducted before the 2000s compared to more recent studies<sup>1</sup>.

The objective of the current research was to assess the possible confounding factors related to these decreasing GMT in more recent studies, through a meta-analysis of RVNA, in healthy individuals, after 14 days or 28 following vaccination in a PEP schedule.



images: Flaticon.com

Reference: 1. Morelli F, Augard C, Bourhy H, Bravo C, Coudeville L, Moore S, Quiambao B, Recuenco S. Immunogenicity of rabies vaccines in postexposure prophylaxis (PEP) or simulated PEP regimens: a systematic literature review and meta-analysis. Presented at: the International Conference on Rabies in the Americas Meeting; 2022 Oct 23-28; Querétaro, Mexico.

## Methods

- This study is a literature review conducted in scientific databases (PubMed, Embase, the Cochrane Library) and internal Sanofi sources, searching publications using **HDCV**, Sanofi **PVRV**, or **PCECV**, presenting **RVNA GMT**, measured using Rapid Fluorescent Focus Inhibition Tests (**RFFIT**), from Jan 1985 to March 2023. Additional studies were also included using a snowballing strategy.
- **Meta-regressions** were conducted using the function 'metareg' in the package 'metafor'<sup>2</sup> in the statistical software environment R<sup>3</sup>. Briefly, this function fits a meta-analytic random-effects model using a linear model framework. The estimator for the amount of heterogeneity in the random-effect model was an empirical Bayes estimator ('method = EB').

image: Generated with AI, powered by DALL·E 3

Reference: 2. Viechtbauer, W. (2010). Conducting Meta-Analyses in R with the metafor Package. Journal of Statistical Software, 36(3), 1-48.

<https://doi.org/10.18637/jss.v036.i03>

3.R Core Team (2023). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.

<https://www.R-project.org/>





# NECTM9

Northern European  
Conference on Travel Medicine  
Denmark Copenhagen May 22-24 2024




The dependent variable for the model was the RVNA GMT. Considering previously known confounding factors for their estimates, **different models** were conducted using the following variables as covariates **separately** and **collectively**


## Methods




**Vaccine type**




**Year of Titration**



**Laboratory**



**Administration Route**



**Coadministration of  
rabies immunoglobulin**



# NECTM9

Northern European  
Conference on Travel Medicine  
Denmark Copenhagen May 22-24 2024



## Results

57 articles were selected representing 90 interventional groups and 5,701 subjects.

	D14				D28			
	Estimate	Standard Error	Z-value	p-value	Estimate	Standard Error	Z-value	p-value
<b>Model 1</b>								
<b>Intercept</b>	2.3348	0.4349	5.3684	<0.0001	2.1706	0.4772	4.5489	<0.0001
<b>Vaccine Type</b>	-0.1177	0.1702	-0.6913	0.4894	0.0279	0.1839	0.1517	0.8794
<b>Model 2</b>								
<b>Intercept</b>	100.6862	17.0069	5.9203	<0.0001	81.2657	19.5427	4.1584	<0.0001
<b>Year of Titration</b>	-0.0492	0.0085	-5.8008	<0.0001	-0.0394	0.0097	-4.0452	<0.0001
<b>Model 3</b>								
<b>Intercept</b>	1.3564	0.2837	4.7814	<0.0001	1.7504	0.3316	5.2787	<0.0001
<b>Laboratory</b>	0.0829	0.0315	26.290	0.0086	0.0549	0.0347	1.5843	0.1131
<b>Model 4</b>								
<b>Intercept</b>	1.1093	0.4398	2.5222	0.0117	0.9913	0.4428	2.2388	0.0252
<b>Administration Route</b>	0.5456	0.2484	21.970	0.0280	0.7386	0.2552	2.8948	0.0038
<b>Model 5</b>								
<b>Intercept</b>	2.3115	0.2795	8.2706	<0.0001	2.4962	0.4031	6.1925	<0.0001
<b>Coadministration of rabies immunoglobulin</b>	-0.1227	0.1171	-10.476	0.2948	-0.1021	0.1517	-0.6731	0.5009

Table. Results of the meta-regressions models for the log of rabies virus neutralizing antibody titers, at 14 and 28 days after vaccination.



# NECTM9

Northern European  
Conference on Travel Medicine  
Denmark Copenhagen May 22-24 2024



## Results

	D14				D28			
	Estimate	Standard Error	Z-value	p-value	Estimate	Standard Error	Z-value	p-value
<b>Model 6</b>								
Intercept	87.4562	18.7206	4.6716	<0.0001	78.6412	23.4155	3.3585	0.0008
Vaccine Type	-0.1932	0.1507	-12.824	0.1997	0.0354	0.1571	0.2255	0.8216
Year of Titration	-0.0427	0.0092	-46.356	<0.0001	-0.0391	0.0116	-3.3702	0.0008
Laboratory	0.0488	0.0290	16.843	0.0921	0.0237	0.0347	0.6825	0.4949
Administration Route	0.2381	0.2377	10.015	0.3166	0.7822	0.2402	3.2569	0.0011
Coadministration of rabies immunoglobulin	-0.0604	0.0997	-0.6062	0.5444	0.1845	0.1386	1.3312	0.1831

Table. Results of the meta-regressions models for the log of rabies virus neutralizing antibody titers, at 14 and 28 days after vaccination.






# NECTM9

Northern European  
Conference on Travel Medicine  
Denmark Copenhagen May 22-24 2024




Meta-regression estimates for the GMT of RVNA and year of titration, at 14 days after vaccination. Each laboratory is represented by a specific color.





# NECTM9

Northern European  
Conference on Travel Medicine  
Denmark Copenhagen May 22-24 2024



Meta-regression estimates for the GMT of RVNA and year of titration, at 28 days after vaccination. Each laboratory is represented by a specific color.



# NECTM9

Northern European  
Conference on Travel Medicine  
Denmark Copenhagen May 22-24 2024



## Conclusions

Some of the **limitations** of our study include the fact that incomplete reports or missing data were addressed through mean imputations of missing values according to routes and regimens. Also, **laboratories comparability** may be challenging due to the low number of institutions providing results throughout several years.

- The RVNA GMT results varied when conducted across **different laboratories**, suggesting a potential influence on the results. However, this does not reach statistical significance when controlled for year of titration
- There is a direct correlation between the **year of titration** and the **RVNA GMT**, with the GMT progressively decreasing in more recent years.



Thank you!

